Industry's First Fluorimetric Assay for Glutaminyl Cyclase

AnaSpec Launches Industry’s First Fluorimetric, 96-well format Assay for Measurement of Glutaminyl Cyclase (QC) Activity - the SensoLyte® Green Glutaminyl Cyclase Activity Assay Kit.
By: AnaSpec
 
 
Inhibition-curve and Biological Samples using SensoLyte Green QC assay
Inhibition-curve and Biological Samples using SensoLyte Green QC assay
 
Spread the Word
Listed Under

Tags:
* Alzheimer S Disease
* Cancer
* Atherosclerosis

Industrys:
* Biotech
* Research

Location:
* Fremont - California - US

Subject:
* Products

FREMONT, Calif. - May 27, 2014 - PRLog -- AnaSpec is pleased to announce the release of the first commercially available 96-well format, fluorimetric assay for measuring Glutaminyl Cyclase (QC) activity - the SensoLyte® Green Glutaminyl Cyclase Activity Assay Kit.

Glutaminyl cyclase (QC), an enzyme found in animals and plants, catalyzes the cyclization of N-terminal Glutamine, and to a lesser extent Glutamate, to pyroglutamate (1). This post-translational modification (PTM) to pyroglutamate, present in many biologically active peptides and proteins, protects against degradation by aminopeptidases and in many cases determines functionality of protein or peptide (2-7).

Pyroglutamate modification sometimes may lead to negative side effects. pGlu (or pE) modified β-amyloid peptides (pGlu-Aβ) aggregate much faster than non-pyroglutamic Aβ and form toxic oligomers that may damage neurons. The aggregation of β-amyloid plaques is one of the hallmarks of Alzheimer’s Disease (8-10). CCL2 (monocyte chemoattractant protein 1, MCP-1), implicated in a number of diseases has in its mature form an N-terminal pGlu. This modification protects it against aminopeptidase degradation, and improves receptor activation and signal transduction in-vitro (11). Increased levels of pE-CCL2 has been implicated in thyroid carcinoma proliferation and metastasis (12), and atherosclerosis (11), and other inflammatory disorders (11). Thus, Glutaminyl Cyclase (QC) inhibitors are attractive drug candidates.

For more information, please visit: https://www.anaspec.com/products/promotions.asp?id=125&col=1&row=1

References
1.Schilling, S. et al. Biol Chem 389, 983 (2008).

2.Kumar, A. et al. Curr Sci 102, 288 (2012).

3.Castaldo, C. et al. PLOS One 8, 1 (2013).

4.Booth, ER. et al. BMC Biol 2, 1 (2004).

5.Schilling, S. et al. Biol Chem 384, 1583 (2003).

6.Huang, W-L. et al. J Mol Biol 401, 374 (2010).

7.Gontsarova, A. et al. Clin Chim Acta 389, 152 (2008).

8.Sullivan, PC. et al. Neur Lett 505, 109 (2011).

9.Wirths, O. et al. J Biol Chem 285, 41517 (2010).

10.Hartlage-Rubsamen, M. et al. Acta Neuropathol 121, 705 (2011).

11.Cynis, H. et al. EMBO Mol Med 3, 545 (2011).

12.Kehlen, A. et al. Endocr Relat Cancer 20, 79 (2012).

AnaSpec, EGT Group

AnaSpec, EGT Group is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and Takyon™ qPCR MasterMixes. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening (HTS) and drug discovery.  AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis.  AnaSpec is certified to ISO 9001:2008.

For more information visit www.anaspec.com

Contact
Cecilia Po
***@anaspec.com
End
Email:***@anaspec.com Email Verified
Tags:Alzheimer S Disease, Cancer, Atherosclerosis
Industry:Biotech, Research
Location:Fremont - California - United States
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
AnaSpec Inc. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share